X-linked thrombocytopenia (XLT) due to WAS mutations: Clinical characteristics, long-term outcome, and treatment options

Blood

Volumn 115, Issue 16, 2010, Pages 3231-3238

  Albert, Michael H ^a   Bittner, Tanja C ^a   Nonoyama, Shigeaki ^b   Notarangelo, Lucia Dora ^c   Burns, Siobhan ^d   Imai, Kohsuke ^b   Espanol, Teresa ^e   Fasth, Anders ^f   Pellier, Isabelle ^g   Strauss, Gabriele ^h   Morio, Tomohiro ⁱ   Gathmann, Benjamin ^j   Noordzij, Jeroen G ^k   Fillat, Cristina ^l   Hoenig, Manfred ^m   Nathrath, Michaela ⁿ   Meindl, Alfons ^o   Pagel, Philipp ⁿ   Wintergerst, Uwe ^p   Fischer, Alain ^q   Thrasher, Adrian J ^d   Belohradsky, Bernd H ^a   Ochs, Hans D ^r   more..

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^c UNIVERSITY OF BRESCIA   (Italy)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

^g ANGERS UNIVERSITY HOSPITAL   (France)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^j UNIVERSITY OF FREIBURG   (Germany)

^k RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^l CENTRE FOR GENOMIC REGULATION CRG   (Spain)

^m UNIVERSITY HOSPITAL ULM   (Germany)

ⁿ TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^o TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^p Krankenhaus St Josef   (Austria)

^q HÔPITAL NECKER ENFANTS MALADES   (France)

^r UNIVERSITY OF WASHINGTON   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; AUTOIMMUNITY; BLEEDING; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; ECZEMA; EVENT FREE SURVIVAL; FEMALE; GENE; GENE MUTATION; GENOTYPE; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SPLENECTOMY; THROMBOCYTOPENIA; WAS GENE; X CHROMOSOME LINKED DISORDER; X LINKED THROMBOCYTOPENIA;

EID: 77951460081     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-09-239087     Document Type: Article

References (43)

1. Wiskott A. Familiärer, angeborener Morbus Werlhofii? Montasschr Kinderheilkd. 1937;68:212-216.
2. Aldrich RA, Steinberg AG, Campbell DC. Pedigree demonstrating a sex-linked recessive condition characterized by draining ears, eczematoid dermatitis and bloody diarrhea. Pediatrics. 1954;13(2):133-139.
3. Binder V, Albert MH, Kabus M, Bertone M, Meindl A, Belohradsky BH. The genotype of the original Wiskott phenotype. N Engl J Med. 2006;355(17): 1790-1793.
4. Canales ML, Mauer AM. Sex-linked hereditary thrombocytopenia as a variant of Wiskott-Aldrich syndrome. N Engl J Med. 1967;277(17):899-901.
5. Murphy S, Oski FA, Gardner FH. Hereditary thrombocytopenia with an intrinsic platelet defect. N Engl J Med. 1969;281(16):857-862.
6. Vestermark B, Vestermark S. Familial sex-linked thrombocytopenia. Acta Paediatr. 1964;53:365-370.
7. Derry JM, Ochs HD, Francke U. Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell. 1994;78(4):635-644. (Pubitemid 24268586)
8. Villa A, Notarangelo L, Macchi P, et al. X-linked thrombocytopenia and Wiskott-Aldrich syndrome are allelic diseases with mutations in the WASP gene. Nat Genet. 1995;9(4):414-417.
9. Zhu Q, Zhang M, Blaese RM, et al. The Wiskott-Aldrich syndrome and X-linked congenital thrombocytopenia are caused by mutations of the same gene. Blood. 1995;86(10):3797-3804.
10. Ochs HD, Filipovich AH, Veys P, Cowan MJ, Kapoor N. Wiskott-Aldrich syndrome: diagnosis, clinical and laboratory manifestations, and treatment. Biol Blood Marrow Transplant. 2009;15(1 suppl):84-90.
11. Ochs HD, Thrasher AJ. The Wiskott-Aldrich syndrome. J Allergy Clin Immunol. 2006;117(4):725-738, quiz 739.
12. Zhu Q, Watanabe C, Liu T, et al. Wiskott-Aldrich syndrome/X-linked thrombocytopenia: WASP gene mutations, protein expression, and phenotype. Blood. 1997;90(7):2680-2689. (Pubitemid 27413478)
13. Lemahieu V, Gastier JM, Francke U. Novel mutations in the Wiskott-Aldrich syndrome protein gene and their effects on transcriptional, translational, and clinical phenotypes. Hum Mutat. 1999; 14(1):54-66. (Pubitemid 29309944)
14. Imai K, Nonoyama S, Ochs HD. WASP (Wiskott-Aldrich syndrome protein) gene mutations and phenotype. Curr Opin Allergy Clin Immunol. 2003;3(6):427-436. (Pubitemid 39149556)
15. Jin Y, Mazza C, Christie JR, et al. Mutations of the Wiskott-Aldrich Syndrome Protein (WASP): hotspots, effect on transcription, and translation and phenotype/genotype correlation. Blood. 2004;104(13):4010-4019. (Pubitemid 39620151)
16. Notarangelo LD, Mazza C, Giliani S, et al. Missense mutations of the WASP gene cause intermittent X-linked thrombocytopenia. Blood. 2002;99(6):2268-2269. (Pubitemid 34525521)
17. Devriendt K, Kim AS, Mathijs G, et al. Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia. Nat Genet. 2001;27(3):313-317. (Pubitemid 32201854)
18. Beel K, Cotter MM, Blatny J, et al. A large kindred with X-linked neutropenia with an I294T mutation of the Wiskott-Aldrich syndrome gene. Br J Haematol. 2009;144(1):120-126.
19. Ancliff PJ, Blundell MP, Cory GO, et al. Two novel activating mutations in the Wiskott-Aldrich syndrome protein result in congenital neutropenia. Blood. 2006;108(7):2182-2189.
20. Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. A multiinstitutional survey of the Wiskott-Aldrich syndrome. J Pediatr. 1994;125(6 Pt 1):876-885.
21. Cooper MD, Chae HP, Lowman JT, Krivit W, Good RA. Wiskott-Aldrich syndrome. An immunologic deficiency disease involving the afferent limb of immunity. Am J Med. 1968;44(4):499-513.
22. Notarangelo LD, Miao CH, Ochs HD. Wiskott-Aldrich syndrome. Curr Opin Hematol. 2008;15(1):30-36.
23. Filipovich AH, Stone JV, Tomany SC, et al. Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. Blood. 2001;97(6):1598-1603.
24. Ozsahin H, Cavazzana-Calvo M, Notarangelo LD, et al. Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. Blood. 2008;111(1):439-445.
25. Boztug K, Dewey RA, Klein C. Development of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome. Curr Opin Mol Ther. 2006;8(5):390-395. (Pubitemid 44566780)
26. Marangoni F, Bosticardo M, Charrier S, et al. Evidence for long-term efficacy and safety of gene therapy for Wiskott-Aldrich Syndrome in preclinical models. Mol Ther. 2009:17(6):1073-1082.
27. Zanta-Boussif MA, Charrier S, Brice-Ouzet A, et al. Validation of a mutated PRE sequence allowing high and sustained transgene expression while abrogating WHV-X protein synthesis: application to the gene therapy of WAS. Gene Ther. 2009:16(5)605-619.
28. Antonarakis SE. Recommendations for a nomenclature system for human gene mutations. Nomenclature Working Group. Hum Mutat. 1998;11(1):1-3.
29. R: A Language and Environment for Statistical Computing [computer program]. Vienna, Austria: R Foundation for Statistical Computing; 2009.
30. Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16(3):1141-1154.
31. Proust A, Guillet B, Pellier I, et al. Recurrent V75M mutation within the Wiskott-Aldrich syndrome protein: description of a homozygous female patient. Eur J Haematol. 2005;75(1):54-59. (Pubitemid 40873962)
32. Andreu N, Matamoros N, Escudero A, Fillat C. Two novel mutations identified in the Wiskott-Aldrich syndrome protein gene cause Wiskott-Aldrich syndrome and thrombocytopenia. Int J Mol Med. 2007;19(5):777-782.
33. Ochs HD, Rosen FS. Wiskott-Aldrich syndrome. In: Ochs HD, Smith CIE, Puck JM, eds. Primary Immunodeficiency Diseases. 2nd ed. New York, NY: Oxford University Press; 2007:454-469.
34. WHO. Life Tables for WHO Member States. http:// apps.who.int/whosis/ database/life-tables/life-tables.cfm. Accessed December 20, 2009.
35. Group USCSW. United States Cancer Statistics: 1999-2005 Incidence and Mortality Web-based Report. www.cdc.gov/uscs. Accessed December 20, 2009.
36. Corash L, Shafer B, Blaese RM. Platelet-associated immunoglobulin, platelet size, and the effect of splenectomy in the Wiskott-Aldrich syndrome. Blood. 1985;65(6):1439-1443. (Pubitemid 15057952)
37. Mullen CA, Anderson KD, Blaese RM. Splenectomy and/or bone marrow transplantation in the management of the Wiskott-Aldrich syndrome: long-term follow-up of 62 cases. Blood. 1993;82(10):2961-2966.
38. Davis BR, Dicola MJ, Prokopishyn NL, et al. Unprecedented diversity of genotypic revertants in lymphocytes of a patient with Wiskott-Aldrich syndrome. Blood. 2008;111(10):5064-5067.
39. Wada T, Konno A, Schurman SH, et al. Second-site mutation in the Wiskott-Aldrich syndrome (WAS) protein gene causes somatic mosaicism in two WAS siblings. J Clin Invest. 2003;111(9):1389-1397. (Pubitemid 36554710)
40. Lum LG, Tubergen DG, Corash L, Blaese RM. Splenectomy in the management of the thrombocytopenia of the Wiskott-Aldrich syndrome. N Engl J Med. 1980;302(16):892-896. (Pubitemid 10143986)
41. Schurman SH, Candotti F. Autoimmunity in Wiskott-Aldrich syndrome. Curr Opin Rheumatol. 2003;15(4):446-453.
42. Dupuis-Girod S, Medioni J, Haddad E, et al. Auto-immunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. Pediatrics. 2003;111(5 Pt 1):e622-627.
43. Perry GS III, Spector BD, Schuman LM, et al. The Wiskott-Aldrich syndrome in the United States and Canada (1892-1979). J Pediatr. 1980;97(1):72-78.